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Abstract
Introduction: Invasive GH-secreting pituitary adenomas are rarely cured by surgery and although
long-term therapy with somatostatin analogs (SSAs) may be employed, hormonal control is achieved
in only 60% of cases. The impact of tumor debulking on subsequent control of acromegaly with SSAs
has not been studied previously.
Methods: We studied retrospectively the response to SSA therapy in acromegalic patients before and
after incomplete surgical tumor excision. A case review identified 24 acromegalic patients who had
received SSA therapy for $1 month before and after gross total resection or debulking of adenomas.
No patient received radiotherapy or combination treatment with SSAs and dopamine agonists during
the study. GH and IGF-I responses to SSAs were recorded pre- and postoperatively. Postoperative SSA
therapy was begun after a washout period of 1–3 months to assess the hormonal effects of the
surgery alone.
Results: Before preoperative SSA treatment, 24/24 (100%) patients had elevated GH levels and IGF-I
levels were elevated in 19/21 (90.5%) patients with recorded values. During preoperative SSA treat-
ment, GH and IGF-I levels were normalized in 7/24 (29.2%) and 11/24 (45.8%) patients respectively.
Following postoperative washout, GH was controlled in only 3/24 (12.5%) patients, while IGF-I was
controlled in 8/19 (42.1%) patients with available data. During the second SSA treatment period,
normal GH levels were seen in 13/24 (54.2%) patients, while IGF-I control was noted in
18/23 (78.3%).
Conclusion: Gross total tumor resection or debulking increases the likelihood of achieving biochemical
disease control with SSAs in acromegalic patients with adenomas that were not amenable to
complete surgical resection and in whom primary SSA therapy was unable to achieve good bio-
chemical control.
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Introduction
Chronic hypersecretion of growth hormone (GH)
results in acromegaly, a disease with multiple compli-
cations, high long-term morbidity and increased
mortality. Three classes of therapy are available for
acromegaly: surgical, medical and radiological (1).
For patients with microadenomas or uncomplicated
macroadenomas, primary therapy is usually adeno-
mectomy, commonly via the transsphenoidal approach.
Patients often receive presurgical treatment with a
somatostatin analog (SSA) in an effort to improve
physical symptoms, to shrink tumors or to influence
tumor morphology favorably. For acromegalic patients
who are unfit for surgery, or in elderly patients with
mild symptoms, primary medical therapy may be advo-
cated, usually with an SSA. The cure rate following
surgery in acromegaly is approximately 50–70%;
thus many patients who do not achieve surgical cure
require subsequent medical or radiation therapy.
There is some controversy about the primary treatment
of acromegaly in patients with complicated tumors
with a low potential for successful surgery (2). This is
particularly true in adenomas with laterosellar exten-
sion or evidence of invasiveness. Many of these patients
will receive SSA therapy in an effort to slow tumor
growth and alleviate symptoms; however, the rate of
therapeutic failure in normalizing all parameters in
this group is significant (40 –60%) (3–5). The impact
of surgery on the hormonal response to SSAs has not
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been studied previously in a series of acromegalic
patients with difficult-to-resect tumors. Therefore, we
performed a retrospective study of the GH and insu-
lin-like growth factor-I (IGF-I) responses to SSAs
before and after subtotal surgical tumor excision.
Patients and methods
Case records of acromegalic patients from two centers
(University Hospital, Lie`ge, Belgium and Biceˆtre Univer-
sity Hospital, Le Kremlin-Biceˆtre, France) were screened
for subjects who had undergone transsphenoidal sur-
gery and who were treated with SSAs before and after
surgery. We identified patients who underwent either
(i) tumor debulking of an unresectable tumor or (ii)
gross total resection that did not lead to complete
tumor excision (Table 1). All patients had to have clini-
cally active acromegaly before and after surgery, and
only patients for whom sufficient GH and IGF-I data
were available during the pre- and post-surgical periods
were included. Preoperative SSA treatment was given
for at least 1 month in all patients, while postoperative
SSA therapy lasted at least 3 months. Patients who
received combination treatment with SSAs and dopa-
mine agonists during the study period were excluded.
No patient had received radiotherapy before or during
the study period. To allow for an adequate washout
period, post-surgical hormonal sampling was per-
formed at least 30 days after surgery and the last
octreotide administration. Three patients were treated
before surgery using long-acting SSAs (lanreotide and
lanreotide autogel), and the post-surgical evaluation
was done after a 3 month period in these patients.
GH and IGF-I measurements
GH and IGF-I were measured at four time points: t0:
baseline data at diagnosis; t1: data during preoperative
SSA treatment; ts0: data after surgery and SSA wash-
out; ts1: data during postoperative SSA treatment.
The following hormonal values were selected: the
basal GH value pre-SSA therapy, the lowest GH value
obtained during SSA therapy and the corresponding
IGF-I levels before and during SSA therapy. GH and
IGF-I concentrations were measured using commer-
cially available kits. ‘Normal’ GH cut-off values have
been lowered in recent years, with the current litera-
ture favoring a value of 2mg/l; thus we chose this
threshold for our study (1). Due to the use of different
assays, IGF-I values were expressed as a percentage of
the upper limit of normal values, normalized for age
and sex for each assay. Thus, the cut-off value for
normalization of IGF-I was 100%.
Statistical analysis
The GH and IGF-I data showed the presence of outliers
in the higher values of the samples. This deviation from
a normal distribution of the samples was confirmed by
Table 1 Patient characteristics and treatment details.
Patient Sex/age Diameter Invasion Treatment Dose
Duration
(months) Surgery Immunohistology Treatment Dose
Duration
(months)
1 M/36 17 — Octr 300 4 1 GH, a-SU Octr 300 2
2 F/39 32 L Octr 300 1 2 GH, PRL Octr 300 2
3 M/48 20 — Octr 600 6 1 GH, PRL Octr 300 4
4 M/34 26 — Octr 900 3 1 GH, ACTH Octr 1500 5
5 F/55 12 — Octr 300 1 1 GH, PRL Octr 200 6
6 F/42 25 — Lanr 60 5 2 GH, PRL Lanr 60 4
7 M/35 26 R Octr 300 3 1 GH, PRL Octr 300 1
8 F/62 18 L Octr 300 5 1 GH Octr 300 7
9 M/36 ,10 — Octr 1500 6 1 GH Octr 400 3
10 M/38 15 — Octr 1500 1 1 GH Octr 300 4
11 M/44 23 L Octr 300 5 2 GH Octr 300 12
12 F/53 14 R Octr 300 5 1 GH Octr 300 3
13 F/36 25 — Octr 300 6 1 GH, PRL Lanr 60 12
14 F/59 12 L Octr 300 7 1 GH, PRL Octr LAR 20 5
15 M/38 16 — Octr 500 3 1 GH, PRL Lanr 90 3
16 F/64 31 — Octr 300 13 2 GH, TSH Octr 300 17
17 F/36 8 — Octr 1500 6 1 GH Octr LAR 30 72
18 F/49 26 R Octr 300 13 1 GH, a-SU Lanr 60 7
19 M/42 30 R Octr 300 9 2 GH, PRL, a-SU Octr 300 36
20 F/39 30 — Octr 300 5 2 GH, PRL Octr 300 4
21 M/15 ,10 R Lanr 60 52 2 GH, a-SU Lanr 60 33
22 F/35 25 L Octr 1500 10 2 GH, PRL Octr 1500 3
23 F/19 24 L Octr 1500 5 2 GH, PRL Octr 1500 4
24 M/41 22 L Lanr AG 90 4 1 GH, PRL Lanr 60 5
Age: age at diagnosis. Diameter: maximal diameter in mm. Invasion: L/R ¼ left/right cavernous sinuses. Treatment/Dose: Octr: octreotide (mg/day), Lanr:
lanreotide (mg/month), Octr: LAR: octreotide LAR (mg/month), Lanr AG: lanreotide autogel (mg/month). Surgery: 1 ¼ gross total resection, 2 ¼ debulking.
PRL, prolactin; ACTH, adrenocorticotropin; TSH, thyrotropin; a-SU, a-subunit.
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quantile –quantile plots and the Kolmogorov –Smirnov
test, showing that the distribution was non-normal.
Therefore, the data were described using the trimmed
mean (xt) with a trimming factor of 0.2. The standard
error (Sew) of the distribution of the trimmed means
was calculated using the Winsorised variance (Sw
2 ) of
the sample for a 95% confidence interval. Due also to
the deviation from the normal distribution, GH and
IGF-I values during SSA treatment, before and after
surgery were compared using the percentile t bootstrap
method for trimmed means, offering a more robust and
unbiased appreciation of the difference between the
means (6, 7). Chi-squared tests were also used to com-
pare the numbers of patients achieving safe IGF-I levels
under SSAs before and after surgery. Data analysis was
performed with the R statistical software (8), with the
additional Rand –Wilcox –Randfunv package for the
standard error and bootstrap routines (9).
Results
The study population consisted of 24 acromegalic
patients. The patients’ demographic and disease
characteristics are shown in Table 1. The mean
durations of SSA treatment before and after surgery
were 7.4^10.0 and 10.6^15.9 months (P ¼ NS)
respectively.
GH responses
The GH responses before and after surgery and SSAs
are shown in Fig. 1 and Table 2. Lowest pretreatment
GH values at t0 showed a wide range (2.6–150mg/l)
with a mean value of 22.2mg/l (Sew: 3.6). Nadir GH
levels were higher than 2mg/l in all patients at t0. At
the end of the first SSA treatment period (t1), nadir
GH levels were significantly lowered to a mean value
of 6.2mg/l (Sew: 1.5, range 0.4 –35.7mg/l). Of the 24
patients, seven (29%) had a nadir GH less than
2mg/l. After surgery, and following a washout period,
the mean nadir GH was 6.7 (Sew: 0.8, range 0.9 –
32.1mg/l). Only three patients (12.5%) had nadir GH
levels of less than 2mg/l. During the second SSA treat-
ment period, GH level nadirs were further decreased to
a mean of 2 (Sew: 0.7) mg/l (range 0.2 –18.6mg/l) and
GH levels were normalized in 13 patients (54%). The
nadir GH values achieved during SSA treatment were
significantly lower after surgery than before
(P , 0.01). Taking patients individually, cut-off GH
values of 2mg/l were achieved in 29.2% of patients at
t1, and in 54.2% of patients at ts1. The mean (xt)
reduction in GH with SSAs before surgery was 69%
(Sew: 6.9), which was similar to that obtained with
the postoperative SSA treatment (69%, Sew: 6.5;
P ¼ 0.99).
IGF-I responses
The IGF-I levels before and after surgery and SSA
therapy are shown in Fig. 2 and Table 2. The mean
IGF-I level at t0 was 203% (Sew: 16, range 77–
737%). This decreased to 106% of normal (Sew: 14,
range 37–647%) at t1. After surgery and washout
(ts0), the mean IGF-I level was 158% (Sew: 17, range
70–316%). The second course of SSA therapy reduced
the mean IGF-I to 78% (Sew: 9, range 20–154%). IGF-I
values achieved during SSA treatment were signifi-
cantly lower after surgery than before (P , 0.01).
The number of patients who achieved safe IGF-I levels
during SSAs was significantly higher after surgery.
At t1, 11/24 (46%) patients achieved normal IGF-I
levels, which rose to 18/23 (78%) patients at ts1
(x2 test, P=0.047).
Figure 1 Box and whisker plots of
GH levels (logarithmic) at the four
time points. The box plots
represent the median and the
interquartile range; the whiskers
represent the extremes of data
ranges. Outlying data points are
plotted individually. The horizontal
dashed line represents the normal
2mg/l cut-off value. Trimmed
means are indicated under
each box.
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Discussion
The optimal choice of treatment for acromegalic
patients with varying disease severity has been a sub-
ject of continuing discussion. Surgical treatment
allows the complete removal of the adenoma in
50–70% of cases, and may definitively cure the
patient. It follows, however, that in a sizeable pro-
portion of cases, complete removal of the adenoma is
not possible, due to extrasellar extension or invasion
of the tumor. Bone and/or dural invasion or intra-
cavernous extension of the tumor reduces the surgical
cure rate in acromegaly. As macroadenomas represent
60–80% of GH-secreting adenomas, this is a signifi-
cant therapeutic challenge (5). Primary medical treat-
ment is considered an adjunct to or an alternative to
surgery in patients with difficult-to-resect tumors.
SSAs, such as octreotide and lanreotide, often in
their long-acting depot formulations, are a useful
option to achieve clinical improvements and poten-
tially shrink tumors. These compounds often allow
good control of GH secretion in patients not cured
by surgery or in cases where surgery is contraindi-
cated (1, 5). The GH antagonist, pegvisomant is also
useful in patients who have an inadequate response
to SSA treatment (10, 11). The therapeutic value of
investigational agents, such as chimerical compounds
that act on somatostatin and dopamine receptors,
remains to be proven. Radiotherapy is third-line
therapy when GH secretion is not sufficiently con-
trolled by surgery and medical treatment, but is of
limited use due to the potential for long-term side
effects resulting from the irradiation of neighboring
structures. As long-term treatment by SSAs permits
the normalization of GH and IGF-I in a substantial
Table 2 Individual GH and IGF-1 values for all patients at the
four study time points.


















1 15.5 164 5.7 168 5.6 — 0.6 —
2 30 131 17.8 107 26.3 82 3.9 81
3 10 — 1.4 526 4.7 89 0.6 105
4 35.1 263 2.7 105 6 316 2.9 150
5 16 227 1 59 8.2 150 1.5 80
6 62 — 9.8 169 6.2 184 2.9 92
7 34 258 1.13 132 4.5 — 0.2 65
8 16.8 190 12 118 6.6 168 2.7 82
9 12.9 211 5.6 200 7.4 253 1.6 74
10 10 179 3.4 74 1.3 — 0.2 42
11 50 133 0.7 117 1.1 129 1 48
12 21.8 180 6.7 62 9.1 84 1.7 44
13 48 — 10.3 82 8 144 5.5 81
14 7.9 164 0.8 37 5.8 76 0.2 34
15 9.3 737 5.3 647 0.9 90 0.4 100
16 2.6 85 0.4 58 3.1 70 0.56 20
17 27.3 300 16.1 136 10.1 — 2.5 141
18 150 250 3.2 77 6.2 106 0.6 27
19 28.5 139 9 147 10 122 12 154
20 12 112 1.9 68 3.6 74 0.3 58
21 26.1 184 35.7 63 11 197 5.5 99
22 35.8 173 17.7 95 32.1 — 18.6 94
23 11.57 77 9.9 56 9.4 74 7.5 47
24 22.5 240 10.6 144 6.38 182 2.9 105
t0: data at diagnosis. t1: data at the end of the preoperative SSAs trial.
ts0: data after surgical debulking. ts1: data at the end of the postoperative
SSAs trial. IGF-I values are expressed as % of upper normal limit. GH cut-
off value: 2mg/l. IGF-I cut-off value: 100%.
Figure 2 Box and whisker plots of
IGF-I levels (logarithmic) at the
four time points. Data are
expressed as a percentage of the
upper limit of normal values, nor-
malized for age and sex for each
assay. The box plots represent
the median and the interquartile
range; the whiskers represent the
extremes of data ranges. Outlying
data points are plotted individually.
The horizontal dashed line rep-
resents the normal 100% cut-off
value. Trimmed means are
indicated under each box.
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number of cases (40 –60%) (12), some physicians may
opt to treat patients suffering from extrasellar macro-
adenomas with SSAs when compression of adjoining
structures is not present (12–17). Whether or not
surgery improves the outcome of medical therapy
with SSAs has not been studied previously. In studies
of octreotide as primary treatment compared with
patients who had undergone pituitary surgery or
irradiation and who were receiving octreotide as
second-line treatment, octreotide was equally effective
(14). We hypothesized that by reducing tumor mass
and decreasing basal GH secretion, the subsequent
control of GH and IGF-I levels with SSAs could be
improved. This hypothesis is consistent with long-
term trials that show a better control of GH and
IGF-I with SSAs when initial GH levels are lower
(12). Patient inclusion for our study was facilitated
by the fact that most acromegalic patients who
undergo surgery at our centers are pretreated with
SSAs for a period of at least 3 months to improve gen-
eral health and facilitate surgical adenoma resection
(18). The results of our study suggests that surgical
reduction of the pituitary tumor mass can enhance
the possibility of achieving postoperative hormonal
control with SSA treatment. In this series, preopera-
tive SSA therapy was associated with adequate GH
and IGF-I responses in approximately 29 and 46% of
patients respectively. In the case of GH, this response
rate is lower than would be expected from published
series, but is not surprising given that patients were
suffering from large, invasive or difficult-to-resect
tumors. Of the 17 patients who did not normalize
GH values with preoperative medical therapy, six
achieved normal GH levels with postoperative SSA
treatment. Of the 13 patients who did not normalize
IGF-I values with preoperative medical therapy, seven
achieved normal IGF-I levels with postoperative SSA
therapy. The magnitude of the decrease in GH with
SSA therapy following surgical debulking was vir-
tually identical to that seen before surgery. This indi-
cates that surgical debulking did not have a
qualitative impact on the responsiveness of GH ade-
noma cells; rather, these results suggest that the mag-
nitude of the effect of SSA on reducing GH secretion in
acromegaly is relatively fixed. Thus, a reduction in the
baseline GH secretion by surgically debulking
increases the likelihood that further reductions in
GH secretion achieved by SSAs would bring patients
toward acceptable hormonal control, and potentially
reduce excess mortality.
In conclusion, this retrospective study shows that in
patients with tumors that were not successfully
removed surgically and in whom primary medical
therapy was unable to produce hormonal control,
gross total resection or debulking of the tumor
increases the probability of achieving hormonal control
with postoperative SSA administration. Even if surgery
is unable to cure acromegaly or qualitatively alter the
response to SSAs, it can permit a higher percentage
of patients to attain safe levels of GH and IGF-I with
subsequent medical therapy.
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